CAS 1630936-95-6

Fórmula: C17H11Cl2N3O2

InChI: InChI=1S/C17H11Cl2N3O2/c18-11-4-7-16(21-10-11)24-15-6-5-12(9-13(15)19)22-17(23)14-3-1-2-8-20-14/h1-10H,(H,22,23)

Chave InChI: MZRLPXFGQKQHST-UHFFFAOYSA-N

SMILES: C1=CC=NC(=C1)C(=O)NC2=CC(=C(C=C2)OC3=NC=C(C=C3)Cl)Cl

VU0422288

CAS: 1630936-95-6

VU0422288

Fórmula: C₁₇H₁₁Cl₂N₃O₂

Pureza: ≥95%

Peso molecular: 360.19

Ref: 54-BUP06323

VU0422288

CAS: 1630936-95-6

VU0422288 (ML396) is a type III mGlu receptor (mGlus) orthosteric modulator with inhibitory effects on mGluR4.VU0422288 can be used to study Rett syndrome.

Fórmula: C₁₇H₁₁Cl₂N₃O₂

Pureza: 99.77%

Cor e Forma: Solid

Peso molecular: 360.19

Ref: TM-T29135

VU 0422288

CAS: 1630936-95-6

Fórmula: C₁₇H₁₁Cl₂N₃O₂

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 360.1941

Ref: IN-DA01E2K8

VU 0422288

Produto Controlado

CAS: 1630936-95-6

Applications VU 0422288 is a metabotropic glutamate receptor 7 (mGlu7) positive allosteric modulators.
References Jalan-Sakrikar, N., et al.: ACS Chem. Neurosci., 5, 1221-1237 (2014);

Fórmula: C₁₇H₁₁Cl₂N₃O₂

Cor e Forma: Neat

Peso molecular: 360.19

Ref: TR-V787590

VU 0422288

CAS: 1630936-95-6

VU 0422288 is a drug that is being studied for the treatment of Alzheimer's disease and other neurological disorders. It is an inhibitor of the metabotropic glutamate receptor (mGluR) type 5 and has been shown to be a potent activator of mGluRs. In animal models, VU 0422288 has been shown to protect against cognitive impairment and reduce amyloid beta production in the brain. It also reduces inflammation in the brain and spinal cord, which may contribute to its therapeutic effects. This drug is not effective for treating dementia or Alzheimer's disease, but it may be useful for treating autoimmune diseases.

Fórmula: C₁₇H₁₁Cl₂N₃O₂

Pureza: Min. 95%

Peso molecular: 360.2 g/mol

Ref: 3D-FQC93695